Login to Your Account

Vanoxerine Mimics DC Cardioversion in Phase IIb Study

By Marie Powers
Staff Writer

Monday, November 18, 2013
Chanrx Corp. moved a step closer to the goal line for lead candidate vanoxerine (GBR-12909), reporting Phase IIb data at the American Heart Association (AHA) 2013 Scientific Sessions suggesting the drug’s efficacy approached that of direct current (DC) cardioversion for patients with atrial fibrillation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription